Key Highlights

● Foghorn Therapeutics closed at $2.02 on Friday, October 2, 2026, a decline of 30.82% on the session.

● Reports indicated that Foghorn’s collaboration with Eli Lilly had ended, and the company moved to reprioritize its pipeline.

● Several analysts responded to the Partnership news by cutting their price targets on the clinical-stage biotech stock.

● The decline came as a weak September jobs report and easing Treasury yields lifted the broader US market.

Foghorn Therapeutics (NASDAQ:FHTX) led Friday’s decliners on the US tape, closing at $2.02, a daily change of -30.82%. The drop stood in stark relief against the broader session, in which US equities rallied after a much weaker-than-expected September jobs report. Nonfarm payrolls rose just 29,000 against consensus for roughly 84,000, and the Unemployment rate ticked up to 4.2%, prompting investors to pare back bets on further Federal Reserve tightening. Treasury yields eased from recent multiyear highs, the benchmark 10-year sitting around 5.24%, and a semiconductor-led advance carried the major indexes to new highs. Foghorn fell sharply while the tape around it climbed, a divergence that pointed to company-specific pressure rather than market-wide flows.

The Lilly Collaboration and Analyst Reaction

Unlike many of the day’s steep micro-cap moves, Foghorn’s decline tracked a clearly identifiable catalyst. Reporting around the session indicated that the company’s collaboration with Eli Lilly (NYSE:LLY) had come to an end, removing a key partner and the validation that such a tie-up had provided for Foghorn’s research platform. Coverage described the company moving to reprioritize its pipeline in the wake of the dissolved arrangement, and several analysts responded by cutting their price targets on the stock. The combination of a lost partnership, a strategic pivot, and a wave of downgrades is the kind of development that can reset a clinical-stage biotech’s perceived value quickly, and Friday’s move appeared to extend a sell-off that had been building as the news circulated.

Why Biotech Shares React So Sharply

Foghorn operates in the clinical-stage biotechnology space, a corner of the market where share prices are driven overwhelmingly by binary, company-specific events: trial readouts, regulatory decisions, and the fate of partnership agreements. Firms at this stage typically generate little or no product Revenue and depend heavily on collaborations and external funding to advance their programs. When a major pharmaceutical partner steps away, the market is left to reassess both the near-term cash runway and the longer-term prospects of the underlying science. That dynamic helps explain why a stock in this category can lose nearly a third of its value in a single session even as the overall market pushes higher.

A Rising Market Highlights the Divergence

The macro backdrop did little to cushion the move and, if anything, highlighted it. The day’s easing in yields and the renewed appetite for growth and technology names lifted large swaths of the market, with chipmakers setting the pace and Nvidia (NASDAQ:NVDA) touching a fresh all-time intraday high on its way to leading the Nasdaq to a new closing high. Rate-sensitive, long-duration Assets such as unprofitable biotechs can benefit when yields fall, yet that tailwind was plainly overwhelmed in Foghorn’s case by the partnership news and the analyst reaction that followed. Elsewhere in commodities, Crude Oil fell roughly 3.9% while gold held firm near all-time highs, neither of which bears directly on a company of Foghorn’s profile.

Why Foghorn’s Drop Stood Apart in Biotech

For context, the broader biotechnology complex saw mixed action on the day, with several speculative names posting outsized gains and others, like Foghorn, falling hard. That split underscores how idiosyncratic these moves tend to be. In Foghorn’s case the signal was relatively clear: the loss of the Eli Lilly collaboration and the accompanying downgrades, rather than any shift in the market’s overall risk appetite, drove the stock’s decline.